|
1
|
López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, Carballido-Fernández M, Pineda-Caplliure A, Mollar-Maseres J, Shalabi Benavent M, Sanz-Herrero F, Zornoza-Moreno M, Pérez-Martín JJ, Alfayate-Miguelez S, Pérez Crespo R, Bastida Sánchez E, Menasalvas-Ruiz AI, Téllez-González MC, Esquiva Soto S, Del Toro Saravia C, Sanz-Muñoz I, Eiros JM, Matías Del Pozo V, Toquero-Asensi M, Pastor-Villalba E, Lluch-Rodrigo JA, Díez-Domingo J, Orrico-Sánchez A. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill 2024; 29:2400046. [PMID: 38333937 PMCID: PMC10853977 DOI: 10.2807/1560-7917.es.2024.29.6.2400046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 02/06/2024] [Indexed: 02/10/2024] Open
Abstract
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.
Collapse
Affiliation(s)
- Mónica López-Lacort
- Vaccine Research Department, Fisabio-Public Health, Valencia, Spain
- These authors contributed equally to this article and share first authorship
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
| | - Cintia Muñoz-Quiles
- Vaccine Research Department, Fisabio-Public Health, Valencia, Spain
- These authors contributed equally to this article and share first authorship
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
| | - Ainara Mira-Iglesias
- Vaccine Research Department, Fisabio-Public Health, Valencia, Spain
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
| | - F Xavier López-Labrador
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
- Virology Laboratory, Fisabio-Public Health, Valencia, Spain
- Department of Microbiology and Ecology, Medical School, University of Valencia, Valencia, Spain
| | - Beatriz Mengual-Chuliá
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
- Virology Laboratory, Fisabio-Public Health, Valencia, Spain
| | | | - Mario Carballido-Fernández
- Hospital General Universitario de Castellón, Castellón, Spain
- Medicine Department, Universidad CEU Cardenal Herrera, Castellón de la Plana, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Javier Díez-Domingo
- Vaccine Research Department, Fisabio-Public Health, Valencia, Spain
- Catholic University of Valencia, Valencia, Spain
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
| | - Alejandro Orrico-Sánchez
- Vaccine Research Department, Fisabio-Public Health, Valencia, Spain
- Catholic University of Valencia, Valencia, Spain
- CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|